VA-REGULA
16.11.2023 09:01:35 CET | Business Wire | Press release
When investigating digital nomads' journey as new clients, Regula compiled a list of the ten most common activities in various locations spanning the United States, United Kingdom, Germany, Spain, United Arab Emirates, and Mexico. They then called upon respondents to pinpoint the activities causing the utmost distress. Through this approach, the survey brought to light a comparative ranking of countries where businesses encounter difficulties in accommodating users who possess foreign identity documents.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231116009610/en/
Regula conducted a survey in which they identified the ten most common activities for digital nomads in various locations, encompassing the United States, United Kingdom, Germany, Spain, United Arab Emirates, and Mexico. They asked respondents to highlight the activities causing the utmost distress. This revealed a list of countries where businesses struggle to accommodate users with foreign passports. (Graphic: Business Wire)
Interestingly, nomads are expressing the most frustration when interacting with organizations offering services in the United States. This revelation comes as a surprise, given that the United States was the most frequented destination for the digital nomad community in 2022.
The most painful verification processes for nomads in the USA are linked to specific stages: crossing the border (21 percent of respondents), checking into a hotel (19 percent), renting accommodations (19 percent), activating a new mobile phone or SIM card (17 percent), and securing a rental car (14 percent).
In the second spot, the United Arab Emirates presents its share of hurdles, particularly in the areas of applying for a visa, navigating the intricacies of medical insurance, and procuring age-restricted products.
On the other end of the spectrum, standing out as a prime example of efficiency for foreigners, is Germany. It boasts a majority of seamless verification processes during critical steps, including applying for a visa, boarding a flight, checking into a hotel, activating a new mobile phone or SIM card, opening a bank account, and completing medical insurance paperwork.
It also needs to be highlighted that identity verification use cases vary depending on the country, shaped by the specific nuances of local migration laws. For instance, digital nomads in the UAE and US tend to apply for work permits more frequently than their counterparts elsewhere.
Race against time
Just imagine the bureaucratic labyrinth of numerous registrations, verifications, and account openings with essential organizations in a new location that must be navigated by nomads within just a few weeks or a month.
The most prevalent issue associated with the verification process, cited by 19 percent of the survey's respondents, revolves around document validity periods. Some identification documents come with expiration dates, and for a digital nomad who is far from their home country, renewing these documents on time can pose significant challenges.
The challenge of providing proof of residency is cited by another 19 percent of respondents. Digital nomads often lack a fixed residential address, making it hard to furnish traditional proof-of-residency documents like utility bills or rental agreements.
Linked to the previous point, 18 percent of respondents highlighted the challenge of frequently changing locations. Constant travel and shifts in location can result in inconsistencies in the information provided during ID verification, potentially causing delays or rejections. Lastly, trust and credibility are a top concern for another 18 percent of nomads. They may encounter skepticism or a lack of trust from institutions due to the unconventional nature of their lifestyle and work arrangements.
“Verification poses a daunting task for digital nomads as each country and business enforces its unique rules, often lacking streamlined processes for foreign document verification. In the era of global mobility, businesses and nations cannot ignore this new breed of customers and need to carefully review their users’ journeys to elevate the standards of identity verification processes, making them both simple and secure,”—said Henry Patishman, Executive Vice President of Identity Verification Solutions at Regula.
*The research was initiated by Regula and conducted by Sapio Research in September 2023 using an online survey of digital nomads and Fraud Prevention decision makers across the Software/Tech, Financial and Banking Services, Technology, Telecoms, Travel and Hospitality sectors, and others. The respondent geography included the US, UK, Germany, Spain, UAE, and Mexico.
About Regula
With our 30+ years of experience in forensic research and the largest library of document templates in the world, we create breakthrough technologies in document and biometric verification. Our hardware and software solutions allow over 1,000 organizations and 80 border control authorities globally to provide top-notch client service without compromising safety, security, or speed.
Regula was named a Representative Vendor in the Gartner® Market Guide for Identity Verification in 2023.
Learn more at regulaforensics.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231116009610/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
